The Concentrated Antibody from Convalescent Plasma Balanced the Dysfunctional Immune Responses in Patients with Critical COVID‐19
Mingfeng Liao,Xuejiao Liao,Jing Yuan,Bing Zhou,Yang Liu,Xiao Jiang,Zhan Zhang,Caiping Guo,Yunjia Zhang,Shuye Zhang,Lei Liu,Zheng Zhang
DOI: https://doi.org/10.1002/ctm2.571
IF: 8.554
2021-01-01
Clinical and Translational Medicine
Abstract:Clinical and Translational MedicineVolume 11, Issue 11 e571 LETTER TO EDITOROpen Access The concentrated antibody from convalescent plasma balanced the dysfunctional immune responses in patients with critical COVID-19 Mingfeng Liao, Mingfeng Liao National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorXuejiao Liao, Xuejiao Liao National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorJing Yuan, Jing Yuan Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, ChinaSearch for more papers by this authorBing Zhou, Bing Zhou National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorYang Liu, Yang Liu National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorXiao Jiang, Xiao Jiang Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, ChinaSearch for more papers by this authorZhan Zhang, Zhan Zhang Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, ChinaSearch for more papers by this authorCaiping Guo, Caiping Guo Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, ChinaSearch for more papers by this authorYunjia Zhang, Yunjia Zhang Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, ChinaSearch for more papers by this authorShuye Zhang, Shuye Zhang Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaSearch for more papers by this authorLei Liu, Corresponding Author Lei Liu [email protected] National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China Correspondence Shuye Zhang, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Lei Liu, Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected] Zheng Zhang, National Clinical Research Center for Infectious Disease, Institute of Hepatology, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected]Search for more papers by this authorZheng Zhang, Corresponding Author Zheng Zhang [email protected] orcid.org/0000-0002-3544-1389 National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China Shenzhen Bay Laboratory, Shenzhen, Guangdong Province, China Correspondence Shuye Zhang, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Lei Liu, Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected] Zheng Zhang, National Clinical Research Center for Infectious Disease, Institute of Hepatology, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected]Search for more papers by this author Mingfeng Liao, Mingfeng Liao National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorXuejiao Liao, Xuejiao Liao National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorJing Yuan, Jing Yuan Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, ChinaSearch for more papers by this authorBing Zhou, Bing Zhou National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorYang Liu, Yang Liu National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, ChinaSearch for more papers by this authorXiao Jiang, Xiao Jiang Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, ChinaSearch for more papers by this authorZhan Zhang, Zhan Zhang Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, ChinaSearch for more papers by this authorCaiping Guo, Caiping Guo Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, ChinaSearch for more papers by this authorYunjia Zhang, Yunjia Zhang Guangdong Province Research & Development Centre of Protein (Peptide) Separation Engineering Technology, Shenzhen, ChinaSearch for more papers by this authorShuye Zhang, Shuye Zhang Shanghai Public Health Clinical Center, Fudan University, Shanghai, ChinaSearch for more papers by this authorLei Liu, Corresponding Author Lei Liu [email protected] National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China Correspondence Shuye Zhang, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Lei Liu, Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected] Zheng Zhang, National Clinical Research Center for Infectious Disease, Institute of Hepatology, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected]Search for more papers by this authorZheng Zhang, Corresponding Author Zheng Zhang [email protected] orcid.org/0000-0002-3544-1389 National Clinical Research Center for Infectious Disease, Institute for Hepatology, Shenzhen Third People's Hospital, The Second Affiliated Hospital, School of Medicine, Southern University of Science and Technology, Shenzhen, Guangdong Province, China Shenzhen Research Center for Communicable Disease Diagnosis and Treatment of Chinese Academy of Medical Science, Shenzhen, Guangdong Province, China Shenzhen Bay Laboratory, Shenzhen, Guangdong Province, China Correspondence Shuye Zhang, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Lei Liu, Department for Infectious Diseases, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected] Zheng Zhang, National Clinical Research Center for Infectious Disease, Institute of Hepatology, Shenzhen Third People's Hospital, Shenzhen, Guangdong Province 518100, China. Email: [email protected]Search for more papers by this author First published: 04 November 2021 https://doi.org/10.1002/ctm2.571 Mingfeng Liao, Xuejiao Liao, Jing Yuan, and Bing Zhou contributed equally to this work. AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Dear Editor, This study found that the concentrated antibody therapy was able to clear residual virus reservoirs, increase neutralizing antibody levels and the overall immune response by enhancing peripheral lymphocyte counts and neutrophil–lymphocyte ratio when given during the early phase of SARS-CoV-2 infection. To the Editor: Due to the absence of specific and effective treatment for coronavirus disease-2019 (COVID-19), antibody therapy is of great interest.1 With the strong specificity, the antibody therapy is suitable for emergency use. While therapeutic antibodies and convalescent plasma were promising and facilitating patient recovery,2-5 the clinical benefit and immunological effects of therapies using plasma and concentrated antibody from convalescent donors remain uncertain. Here, we conducted a non-randomized clinical trial using concentrated antibodies to treat critically ill COVID-19 patients. Thirteen COVID-19 patients were enrolled in this study at the Shenzhen Third People's Hospital from late January to August, 2020. The demographic data of the patients were shown in Table 1. Seven patients (S1–S7) received concentrated antibody and (or) convalescent plasma treatment as the intervention group, and the other six patients (S8–S13) without no plasma or antibody therapy were followed as the control group. Health history of the both groups showed a very slight and nonsignificant difference (Table S1). Concentrated antibodies were derived from the plasma of fourteen convalescent COVID-19 donors (Table 2, Supplemental Methods and Materials). TABLE 1. Clinical characteristics of 13 COVID-19 patients at Shenzhen third people's hospital, January to August 2020 S1 S2 S3 S4 S5 S6 S7 S8 S9 S10 S11 S12 S13 Severity Critical Critical Critical Critical Critical Critical Critical Critical Critical Critical Critical Critical Critical Age (years) 46 73 69 64 69 70 29 72 36 69 57 66 63 Gender Male Male Male Female Male Female Male Male Male Male Female Male Female Wuhan traveling Yes Yes Yes No No No No Yes No Yes No No No Symptom onset date/first symptom 2020-1-21 Fever, cough 2020-1-20 Fever 2020-1-21 Fever, dizzy 2020-1-29 Fever, cough 2020-1-31 Fever 2020-3-4 Fever 2020-4-24 Fever 2020-1-4 Fever, cough 2020-1-19 Fever, cough 2020-1-11 Fever, cough, pharyngeal pain 2020-1-21 Dizzy, cough, pharyngeal pain 2020-1-20 Fever, weak 2020-1-12 Fever, cough Hospitalization date 2020-1-22 2020-1-22 2020-1-24 2020-2-7 2020-2-3 2020-3-6 2020-4-27 2020-1-20 2020-1-28 2020-1-20 2020-1-23 2020-1-24 2020-1-27 Convalescent Plasma Transfusion (date) ND Yes 2020-2-13; 2020-2-23 ND ND Yes 2020-2-15 ND Yes 2020-5-3 ND ND ND ND ND ND Neutralizing antibody Transfusion (date) Yes 2020-2-2 Yes 2020-2-2; 2020-3-7 Yes 2020-2-19 Yes 2020-2-19 Yes 2020-2-19 2020-3-7 Yes 2020-3-12 Yes 2020-5-1 ND ND ND ND ND ND Outcome/date Cured 2020-3-8 Death 2020-7-23 Death 2020-2-26 Cured 2020-3-11 Death 2020-10-10 Cured 2020-4-1 Cured 2020-5-21 Cured 2020-2-23 Cured 2020-2-26 Cured 2020-2-8 Cured 2020-3-7 Cured 2020-3-6 Cured 2020-3-6 Chronic basic disease None HTN Diabetes SP HTN Coronary heart disease Diabetes HTN None HTN None None None Medication history None None None None None None None None None None None None None SARS-CoV-2 RT-qPCR (Ct value, Before or Transfusion Day)/sample +(30.97) BALF 2020-2-2 +(27.67) Throat swab 2020-2-2 +(36.2) Sputum 2020-2-19 +(37.8) Nasal swab 2020-02-19 +(27.7) Sputum 2020-2-19 +(26.3) Sputum 2020-3-12 +(40) Nasal swab 2020-4-28 +(21.6) Sputum 2020-1-28 +(24.8) Nasal swab 2020-2-10 +(23) Sputum 2020-1-20 +(22.5) Throat swab 2020-1-24 +(26.5) Throat swab 2020-1-24 +(23.8) Nasal swab 2020-1-30 Flu A/B –/– –/– –/– –/– –/– –/– –/– –/– –/– –/– –/– –/– –/– RSV virus – – – – – – – – – – – – – Adenovirus – – – – – – – – – – – – – Interferon atomization 2020-1-22 2020-1-22 2020-1-24 2020-2-7 2020-2-4 2020-3-6 2020-4-27 2020-1-20 2020-1-28 2020-1-20 2020-1-23 No No Ribavirin 2020-1-23 2020-1-22 NO 2020-2-12 2020-2-11 No No 2020-1-20 No 2020-1-20 No No No Methylprednisolone Yes Yes Yes Yes Yes No Yes Yes Yes No Yes Yes Yes SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; RT-PCR, reverse transcription polymerase chain reaction; Ct, cycle threshold; BALF, bronchoalveolar lavage fluid; HTN, hypertension; SP, schizophrenic; Flu, influenza. TABLE 2. Characteristics and antibody titer of convalescent plasma donors Number Gender Age Disease severity Interval between symptom onset and discharge Interval between discharge and plasma donation Donated plasma volume (ml) Blood type For antibody therapy For convalescent plasma RBD-specific IgG ELISA titer RBD-specific IgM ELISA titer Neutralizing antibody titer Infectious pathogen 1 Male 36 Moderate 17 4 500 B+ Yes – 200 1800 NT – 2 Male 35 Moderate 15 8 500 O+ Yes – 600 600 NT – 3 Male 51 Moderate 18 11 300 O+ Yes – 278 612 670 NT – 4 Female 52 Moderate 18 9 500 O+ Yes – NT NT NT – 5 Male 42 Moderate 16 14 500 O+ Yes – 259 418 171 002 NT – 6 Male 51 Moderate 24 5 500 A+ Yes – 16 200 48 600 NT – 7 Male 19 Moderate 22 5 500 A+ Yes – 16 200 48 600 NT – 8 Female 49 Moderate 20 17 480 A+ Yes – 112 720 6053 NT – 9 Female 50 Moderate 19 16 400 B+ Yes – 671 429 102 565 NT – 10 Male 54 Moderate 16 16 400 B+ Yes – 16 200 16 200 NT – 11 Male 47 Severe 34 23 400 B+ Yes – 437 400 437 400 NT – 12 Female 36 Moderate 22 23 400 O+ Yes – 48 600 16 200 NT – 13 Female 47 Moderate 27 21 400 0+ Yes – 16 200 16 200 NT – 14 Male 28 Moderate 15 22 400 AB+ Yes – 16 200 48 600 NT – RBD, receptor-binding domain; IgG, immunoglobulin G; ELISA, enzyme-linked immunosorbent assay. We first investigated the effects of concentrated antibody on viral clearance. The virus Ct values began to increase after two days of concentrated antibody treatment and were then remained undetectable within 10 days posttransfusion for 6 treated patients (Figure 1A). In contrast, SARS-COV-2 in the control group was cleared at 14–48 days postsymptom onset (Figure S1A). The virus titer decreased significantly after concentrated antibody treatment (P = 0.00204) (Figure S1B). FIGURE 1Open in figure viewerPowerPoint Monitoring SARS-CoV-2 viral loads among the enrolled COVID-19 patients. (A) The serial viral Ct values in concentrated antibody therapy group; (B) Representative Viral-Track analysis data. For each potential viral genome, represented by a dot, the entropy of the sequence (how repetitive are the mapped sequences) and the percentage of the segment that is mapped are plotted. Green dots correspond to viral segments that have passed quality control. Viral genomes with more than 50 mapped reads are plotted. (C) Viral-Track analysis of SARS-CoV-2 reads in BALF scRNA-seq data collected before and after the antibody treatment. D0 is the symptom onset date in (A). The square cross indicates the reception of the convalescent plasma transfusion and the diamond plus indicates the reception of concentrated neutralizing antibody treatment as indicated. Tombstone indicates fatal patients (S2, S3, S5). Pedestrian indicates cured patients (S1, S4, S6, S7) We and others have detected residual virus in lung tissues even though continuous SARS-CoV-2 negativity in the nasal, throat swabs and sputum.6, 7 It was proposed that the ongoing viral activity may contribute to COVID-19 severity. Thus, we questioned whether the concentrated antibody therapy could clear the virus reservoir. We applied Viral-Track8 mining the scRNA-seq data of Bronchoalveolar lavage fluid (BALF) samples from two patients before and after the antibody treatment. Total numbers of viral reads mapped to the SARS-CoV-2 viral genome were 7, 460 for S1, and 178 for S2 before the antibody treatment, respectively (Figure 1C); in contrast, no viral read was detected in samples after the treatment. We further confirmed the SARS-CoV-2 as the only virus in the analyzed data with Viral-Track (Figure 1B). The viral reads were found to be enriched in the epithelial cells, plasma cells, macrophages and T cells (Figure S1C). The pathway analysis indicated an enhanced antiviral function of T cells after treatment (Figure S2). Previous studies have reported the decreased T cell counts in peripheral blood of COVID-19 patients; particularly, the decreased CD8 T cells were significantly correlated with disease severity.9 Here, we explore whether the antibody therapy affects cellular immunity. We found the concentrated antibody treatment significantly increased T cell counts in peripheral blood (Figure S3A–C). Importantly, the CD8/CD4 ratio in cured patients receiving concentrated antibody (S1, S4, S6, S7) was remained above 0.5 from 8–17 days after symptom onset, except for patient S6 whose CD8/CD4 ratio was always below 0.5 (Figure S3D; this value was the lower limitation of CD8/CD4 ratio in healthy Chinese adults). By contrast, among those patients with fatal outcomes (S2, S3, S5) even receiving concentrated antibody, the CD8/CD4 ratio decreased and reached the lowest point at 13–16 days postsymptoms onset (Figure S3E). In the control group, the CD8/CD4 ratio gradually decreased after disease onset, reaching the lowest point 14–24 days after symptom onset (Figure S3F, Extended Data 1). Neutrophil–lymphocyte ratio (NLR) was also correlated with COVID-19 severity and prognosis, and the NLR more than 11.75 is strongly associated with the higher mortality. In the current study, the NLR was remained below 11.75 in most of the cured patients (Figure S3G) although it fluctuated greatly at higher levels in the fatal patients (Figure S3H). In the control group, the NLR fluctuated until 14–28 days postdisease onset (Figure S3I). The right timing for antibody therapy is still unclear. We hypothesized that early treatment would favor the recipient to initialize robust antibody response by themselves. Patient S1, S5, S6, and S7 started therapy at 12, 8, 7, and 7 days after the symptoms onset, respectively. They showed increased neutralizing antibody titers along with the increased IgG, IgM, IgA, and total immmunoglobulin concentrations after the concentrated antibody treatment (Figure 2A, B). In contrast, patient S3 and S4 received the concentrated antibody therapy at 29 and 21 days after the symptoms onset, respectively. Little improvement in either neutralizing or total antibodies was observed by the treatment in the two patients (Figure 2A, B). Patient S2 received the treatment at 13 days after the symptom onset. The total immmunoglobulin and neutralizing antibody levels reach stable high level after the antibody transfusion (Figure 2B). These preliminary data indicated that the earlier Ab treatment possibly facilitated disease recovery from severe COVID-19. FIGURE 2Open in figure viewerPowerPoint Monitoring binding antibody and neutralizing antibody levels among the treated COVID-19 patients. The levels of neutralizing antibody and RBD-binding antibody (IgG, IgM, IgA, and total Ig) before and after concentrated antibody therapy in treated patients S1–S7. (A) Cured patients (S1, S4, S6, S7); (B) fatal patients (S2, S3, S5) We suspect that the antibody therapy may also affect proinflammatory responses because antibody-dependent cytokine release (ADCR). Plasma IL-6, procalcitonin, and C-reacting protein (CRP) were dynamically monitored. After antibody treatment, the IL-6 levels were increased rapidly in six of the seven patients (Figure S4A). Notably, IL-6 in patient S2 remained at a lower level for 30 days after the first antibody treatment, but showed a transient increase after the second antibody treatment then followed by decrease to low levels (Figure S4B). We also observed the similar changes of CRP, procalcitonin mirrored IL-6 patterns in patient S1 to S7 (Figure S4C–F). In summary, we found that concentrated antibody therapy may help clear viral reservoirs in infected lung tissues of critical COVID-19 patients, likely through antibody mediated effector functions. Although the transfused antibodies may cause a transient increase of the inflammatory cytokines, they contribute to the improvement of the overall immune homeostasis and could be used during the early phase of COVID-19. These findings provide novel evidences for ongoing monoclonal antibody therapy for COVID-19. ACKNOWLEDGMENTS The authors wish to thank the Cell Bank and clinical staff of the Shenzhen Third People's Hospital for biosamples and services provided in the study. FUNDING INFORMATION This study was supported by the National Science Fund for Distinguished Young Scholars (82025022), the Science and Technology Innovation Committee of Shenzhen Municipality (JSGG20200207155251653, JSGG20200807171401008, KQTD20200909113758004), and the Guangdong Basic Applied Basic Research Foundation (2020B111122002 and 2020B1111340035). CONFLICT OF INTEREST The authors declare that there is no conflict of interest. Supporting Information Filename Description ctm2571-sup-0001-SuppMat.docx46.7 KB Supporting Information ctm2571-sup-0002-FigureCaption.docx32.6 KB Supporting Information ctm2571-sup-0003-FigureS1.tif602.3 KB Supporting Information ctm2571-sup-0004-FigureS2.tif245.4 KB Supporting Information ctm2571-sup-0005-FigureS3.tif328.7 KB Supporting Information ctm2571-sup-0006-FigureS4.tif317.5 KB Supporting Information ctm2571-sup-0007-Table1.docx17.4 KB Supporting Information Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article. REFERENCES 1Taylor PC, Adams AC, Hufford MM, de la Torre I, Winthrop K, Gottlieb RL. Neutralizing monoclonal antibodies for treatment of COVID-19. Nat Rev Immunol. 2021; 21: 382- 393. 2Libster R, Pérez Marc G, Wappner D, et al. early high-titer plasma therapy to prevent severe COVID-19 in older adults. N Engl J Med. 2021; 384: 610- 618. 3Joyner MJ, Senefeld JW, Klassen SA, et al. Effect of convalescent plasma on mortality among hospitalized patients with COVID-19: initial three-month experience. medRxiv. 2020. 4Chen P, Nirula A, Heller B, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med. 2021. 5Marovich M, Mascola JR, Cohen MS. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020; 324: 131- 132. 6Xu G, Liu Y, Liao M, et al. Persistent viral activity, cytokine storm, and lung fibrosis in a case of severe COVID-19. Clin Transl Med. 2020; 10:e224. 7Yao XH, He ZC, Li TY, et al. Pathological evidence for residual SARS-CoV-2 in pulmonary tissues of a ready-for-discharge patient. Cell Res. 2020; 30: 541- 543. 8Bost P, Giladi A, Liu Y, et al. Host-viral infection maps reveal signatures of severe COVID-19 patients. Cell. 2020; 181: 1475- 1488. e1412. 9Zhang Y, Mo P, Ma Z, et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J Infect Dis. 2020; 221: 1762- 1769. Volume11, Issue11November 2021e571 FiguresReferencesRelatedInformation